Diabetes mellitus and ovarian cancer: More complex than just increasing risk

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 273-277

  Shah, Monjri M ^a   Erickson, Britt K ^a   Matin, Tasnia ^b   McGwin, Gerald ^c   Martin, Jovana Y ^a   Daily, Laura Becca ^a   Pasko, Daniel ^a   Haygood, Christen W ^a   Fauci, Janelle M ^a   Leath, Charles A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Body mass index; Diabetes; Outcomes; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; METFORMIN; ANTIDIABETIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CHI SQUARE TEST; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; STUDENT T TEST; ADENOCARCINOMA, PAPILLARY; CARCINOMA, ENDOMETRIOID; COMORBIDITY; COMPLICATION; EPIDEMIOLOGY; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARIAN NEOPLASMS; PROGNOSIS;

ADENOCARCINOMA, PAPILLARY; AGED; CARCINOMA, ENDOMETRIOID; COMORBIDITY; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBESITY; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84913605403     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.09.004     Document Type: Article

References (40)

1. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of childhood and adult obesity in the United States, 2011-2012 JAMA 311 2014 806 814
2. L.R. Howe, K. Subbaramaiah, C.A. Hudis, and A.J. Dannenberg Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer Clin Cancer Res 19 2013 6074 6083
3. Fast Facts: Data and Statistics about Diabetes Accessed April 5, 2014, at http://professional.diabetes.org/admin/UserFiles/0%20-%20Sean/FastFacts%20March%202013.pdf 2013
4. P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri Diabetes and cancer Endocr Relat Cancer 16 2009 1103 1123
5. S.S. Coughlin, E.E. Calle, L.R. Teras, J. Petrelli, and M.J. Thun Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 2004 1160 1167
6. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
7. B.B. Barone, H.C. Yeh, and C.F. Snyder Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis JAMA 300 2008 2754 2764
8. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies PLoS Med 9 2012 e1001200
9. X. Ma, A. Beeghly-Fadiel, and X.O. Shu Anthropometric measures and epithelial ovarian cancer risk among Chinese women: results from the Shanghai Women's Health Study Br J Cancer 109 2013 751 755
10. C.M. Olsen, C.M. Nagle, and D.C. Whiteman Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium Endocr Relat Cancer 20 2013 251 262
11. E.S. Diaz, B.Y. Karlan, and A.J. Li Obesity-associated adipokines correlate with survival in epithelial ovarian cancer Gynecol Oncol 129 2013 353 357
12. J.C. Pavelka, R.S. Brown, and B.Y. Karlan Effect of obesity on survival in epithelial ovarian cancer Cancer 107 2006 1520 1524
13. M.M. Protani, C.M. Nagle, and P.M. Webb Obesity and ovarian cancer survival: a systematic review and meta-analysis Cancer Prev Res (Phila) 5 2012 901 910
14. M. Greenwood, and F. Wood The relation between the cancer and diabetes death-rates J Hyg 14 1914 83 118
15. E. Giovannucci, D.M. Harlan, and M.C. Archer Diabetes and cancer: a consensus report CA Cancer J Clin 60 2010 207 221
16. R. Malaguarnera, and A. Belfiore The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells Front Endocrinol 5 10 2014 [Lausanne]
17. E.J. Gallagher, and D. LeRoith Minireview: IGF, insulin, and cancer Endocrinology 152 2011 2546 2551
18. M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat Rev Cancer 12 2012 159 169
19. R.A. Sayer, J.M. Lancaster, and J. Pittman High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer Gynecol Oncol 96 2005 355 361
20. H. Yu, and T. Rohan Role of the insulin-like growth factor family in cancer development and progression J Natl Cancer Inst 92 2000 1472 1489
21. E.L. Ding, Y. Song, and J.E. Manson Sex hormone-binding globulin and risk of type 2 diabetes in women and men N Engl J Med 361 2009 1152 1163
22. I.R. Wallace, M.C. McKinley, P.M. Bell, and S.J. Hunter Sex hormone binding globulin and insulin resistance Clin Endocrinol (Oxf) 78 2013 321 329
23. M.J. Laws, A. Kannan, S. Pawar, W.M. Haschek, M.K. Bagchi, and I.C. Bagchi Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice PLoS Genet 10 2014 e1004230
24. M.C. Amato, G. Pizzolanti, V. Torregrossa, G. Misiano, S. Milano, and C. Giordano Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes PLoS One 9 2014 e91969
25. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 2009 798 809
26. S.L. Habib, and M. Rojna Diabetes and risk of cancer ISRN Oncol 2013 2013 583786
27. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and K. Struhl Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res 69 2009 7507 7511
28. M. Martin, and R. Marais Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol 30 2012 2698 2700
29. R. Rattan, R. Ali Fehmi, and A. Munkarah Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis J Oncol 2012 2012 928127
30. L.A. Cantrell, C. Zhou, A. Mendivil, K.M. Malloy, P.A. Gehrig, and V.L. Bae-Jump Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy Gynecol Oncol 116 2010 92 98
31. P. Dilokthornsakul, N. Chaiyakunapruk, W. Termrungruanglert, C. Pratoomsoot, S. Saokeaw, and R. Sruamsiri The effects of metformin on ovarian cancer: a systematic review Int J Gynecol Cancer 23 2013 1544 1551
32. W.H. Gotlieb, J. Saumet, and M.C. Beauchamp In vitro metformin anti-neoplastic activity in epithelial ovarian cancer Gynecol Oncol 110 2008 246 250
33. E. Ozbek, A. Otunctemur, and M. Dursun Association between the metabolic syndrome and high tumor grade and stage of primary urothelial cell carcinoma of the bladder Asian Pac J Cancer Prev 15 2014 1447 1451
34. K.Y. Fan, A.S. Dholakia, and A.T. Wild Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer J Natl Compr Canc Netw 12 2014 50 57
35. C.M. Friedenreich, H.K. Neilson, and B.M. Lynch State of the epidemiological evidence on physical activity and cancer prevention Eur J Cancer 46 2010 2593 2604
36. M.E. Levine, J.A. Suarez, and S. Brandhorst Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population Cell Metab 19 2014 407 417
37. L. Makowski, C. Zhou, and Y. Zhong Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer Gynecol Oncol 133 2014 90 97
38. Y. Zhou, R. Chlebowski, and M.J. Lamonte Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative Gynecol Oncol 133 2014 4 10
39. J.C. de Beer, and L. Liebenberg Does cancer risk increase with HbA, independent of diabetes? Br J Cancer 110 2014 2361 2368
40. O. Zivanovic, C.S. Sima, and A. Iasonos The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum Gynecol Oncol 116 2010 351 357